These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 17175893

  • 1. Monitoring cardiac function by B-type natriuretic peptide (BNP) in patients with infantile Pompe's disease treated with recombinant alpha-glucosidase.
    Hahn A, Schmidt D, Hagel KJ, Neubauer BA, Katz N.
    Clin Lab; 2006; 52(11-12):615-9. PubMed ID: 17175893
    [Abstract] [Full Text] [Related]

  • 2. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy.
    Winkel LP, Kamphoven JH, van den Hout HJ, Severijnen LA, van Doorn PA, Reuser AJ, van der Ploeg AT.
    Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987
    [Abstract] [Full Text] [Related]

  • 3. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up.
    Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT.
    Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888
    [Abstract] [Full Text] [Related]

  • 4. [Enzyme replacement therapy in Pompe's disease].
    Merk T, Wibmer T, Schumann C, Krüger S.
    Med Klin (Munich); 2007 Jul 15; 102(7):570-3. PubMed ID: 17634875
    [Abstract] [Full Text] [Related]

  • 5. [Pompe's disease: the role for early diagnosis and treatment].
    Cerini E, Bini M, Donati A, Andaloro L, Compagnoni G.
    Pediatr Med Chir; 2007 Jul 15; 29(5):270-2. PubMed ID: 18402397
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial.
    Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, Wallot M, Richards S, Voit T.
    Neuromuscul Disord; 2005 Jan 15; 15(1):24-31. PubMed ID: 15639117
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.
    Klinge L, Straub V, Neudorf U, Voit T.
    Neuropediatrics; 2005 Feb 15; 36(1):6-11. PubMed ID: 15776317
    [Abstract] [Full Text] [Related]

  • 12. Pompe's disease.
    van der Ploeg AT, Reuser AJ.
    Lancet; 2008 Oct 11; 372(9646):1342-53. PubMed ID: 18929906
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Treatment of Pompe's disease with recombinant enzymes].
    Van Hove JL.
    Verh K Acad Geneeskd Belg; 1998 Oct 11; 60(4):347-57. PubMed ID: 9883081
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Late-onset Pompe's disease.
    Teener JW.
    Semin Neurol; 2012 Nov 11; 32(5):506-11. PubMed ID: 23677658
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Pompe's disease. Part I: pathogenesis and clinical features].
    Illés Z, Trauninger A.
    Ideggyogy Sz; 2009 Jul 30; 62(7-8):231-43. PubMed ID: 19685701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.